Nexus Pharmaceuticals announced the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress.
Sodium Nitroprusside Injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.
Nexus Pharmaceuticals is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products.